Member Info for jmfw

Ice. Selling up & being researched nothing to do with my comment. There will be a rns soon the contents of which will determine whether or not 95p is wonderful opportunity or not. Should it only tell us a 5th cohort is planned, I wouldn't be surprised if the sp reaction was to drop below the open offer. Hopefully, we will get an heads up on the data.

Ice. Think it matters insomuch that the sp is likely to suffer once again. It might make 95p look expensive. Ofcourse, lth have endured numerous such events, but suppose that's the dilemma.

Hope their pain & anguish is chronic.

As did I, MrA. My overall experience led me to discontinue my sub.

Gmcc. Wasn't meant as a correction. I have no idea about the technicalities of the therapeutics, so rely on contributors like yourself to highlight & discuss possibilities & ramifications. I'm invested here because the technology is disruptive, advanced, & endorsed by companies within the biotech arena (witnessed by the jv & licensees).

Gmcc. Affimer comparison to JAM20 is made under the heading
'JAM20 Bound to a Binding Hot Spot within the Switch Region of RAS.'

How would the jv & the partnerships play into such a scenario?

Does seem odd that the sp remains flat in the face of (apparent) overwhelming buying activity during past 24 hours.

821 shares / 100k

Oh dear!

Those guys that have been posting that a raise was imminent have proved correct. However, the scenario they envisaged completely wrong. Suggests to me someone had inside knowledge that was interpreted incorrectly.

Sudden increase in turnover & sp??

If there is a deal to be done, it probably already has been (in principle). It's unlikely that
anything be announced prior to the (official) P1a data release as it would give game away.

MrR, for info, it wasn't lifted, it is MF's article.
'10 stocks we like better than POINT Biopharma Global Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.'

Totally agree, if the reported buys/sells are correct. Only other scenario I can think of is a large buy in the background & the mms are 'farming'.

RAH re "I also suspect AVCT will nearly be out of cash come early November." Why?

What intrigues me about the (apparent) huge disparity between buys/sells, is the amount of 'stock' that is readily available. It seems that there is a large amount of free shares circulating, but where from.......unless there is another large background 'short', or someone has unloaded a significant holding (Medusa directors?). Or maybe the trading range is so tight the algo can't call a trade correctly. I have noticed in very recent times there have been a few occasions the same has happened.

Energy yr 20.58, no reason to believe they've moved on. Rapid Tests are included under 'categories'.

For info I use iweb. Because these are otc shares & not listed on a major Exchange (in US) they are unable to transact on my behalf.
Amongst several others I found Schwab's appraisal of OTCs useful, & discouraging. Good luck ACUT holders.
https://www.schwab.com/stocks/understand-stocks/otc-stock

According to the rns 8 April there are 254,901,919 shares. According to shorttracker Jupiter & Bronte are short by a total 1.08% = some 2.75m